Skip to main content
SpringerLink
Log in

Molecular Markers of Lymph Node Disease in Melanoma

  • Chapter
  • First Online:
Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

Part of the book series: Current Clinical Pathology ((CCPATH))

  • 868 Accesses

Abstract

The molecular profiling of primary melanoma tumors and sentinel lymph node (SLN) specimens might improve patients’ stratification according to their risk of disease progression, and thus the selection for surgical (e.g., radical lymph node dissection) and medical (e.g., interferon-alpha and molecular targeted strategies) therapies. SLN status represents the most important prognostic factor in early-stage melanoma patients. Approximately 80% of patients undergoing sentinel lymph node biopsy (SLNB) will have negative results. Molecular profiling of primary melanomas might add important predictive information to the currently used clinico-histopathological features for predicting SLN status.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med. 1977;297(12):627–30.

    PubMed  CAS  Google Scholar 

  2. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61(9):697–705.

    PubMed  CAS  Google Scholar 

  3. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392–9.

    PubMed  CAS  Google Scholar 

  4. Chen SL, Iddings DM, Scheri RP, Bilchik AJ. Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin. 2006;56(5):292–309. quiz 316–297.

    PubMed  Google Scholar 

  5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging system. J Clin Oncol. 2001;19(16):3622–34.

    PubMed  CAS  Google Scholar 

  6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635–48.

    PubMed  CAS  Google Scholar 

  7. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307–17.

    PubMed  CAS  Google Scholar 

  8. Pasquali S, Mocellin S, Campana LG, et al. Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases: personal experience and literature meta-analysis. Cancer. 2010;116(5):1201–9.

    PubMed  Google Scholar 

  9. Rossi CR, Pasquali S, Mocellin S. Actual false-negative rate prompts the routine use of ultrasound scan before and after sentinel node biopsy in melanoma. Ann Surg Oncol. 2008;15(10):2976–7.

    PubMed  Google Scholar 

  10. Testori A, De Salvo GL, Montesco MC, et al. Italian Melanoma I. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009;16(7):2018–27.

    PubMed  Google Scholar 

  11. Nieweg OE. False-negative sentinel node biopsy. Ann Surg Oncol. 2009;16(8):2089–91.

    PubMed  Google Scholar 

  12. Nieweg OE, Estourgie SH. What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol. 2004;11(3 Suppl):169S–73.

    PubMed  Google Scholar 

  13. Thompson JF, Stretch JR, Uren RF, Ka VS, Scolyer RA. Sentinel node biopsy for melanoma: where have we been and where are we going? Ann Surg Oncol. 2004;11(3 Suppl):147S–51.

    PubMed  Google Scholar 

  14. Scolyer RA, Thompson JF, Li LX, et al. Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Ann Surg Oncol. 2004;11(3 Suppl):174S–8.

    PubMed  Google Scholar 

  15. Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol. 2005;12(6):429–39.

    PubMed  Google Scholar 

  16. Karim RZ, Scolyer RA, Li W, et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg. 2008;247(6):1003–10.

    PubMed  Google Scholar 

  17. Lam TK, Uren RF, Scolyer RA, Quinn MJ, Shannon KF, Thompson JF. False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res. 2009;19(2):94–9.

    PubMed  Google Scholar 

  18. Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in melanoma? Ann Surg Oncol. 2010;17(3):670–3.

    PubMed  Google Scholar 

  19. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365(9460):687–701.

    PubMed  CAS  Google Scholar 

  20. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302–11. discussion 311–303.

    PubMed  Google Scholar 

  21. Morton RL, Howard K, Thompson JF. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol. 2009;16(4):929–40.

    PubMed  CAS  Google Scholar 

  22. Mocellin S, Thompson JF, Pasquali S, et al. Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n  =  1132). Ann Surg. 2009;250(6):964–9.

    PubMed  Google Scholar 

  23. Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4): 282–8.

    PubMed  Google Scholar 

  24. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374(9687):362–5.

    PubMed  Google Scholar 

  25. Kashani-Sabet M, Venna S, Nosrati M, et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res. 2009;15(22):6987–92.

    PubMed  CAS  Google Scholar 

  26. Dadras SS, Lange-Asschenfeldt B, Velasco P, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol. 2005;18(9):1232–42.

    PubMed  Google Scholar 

  27. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol. 2003;162(6):1951–60.

    PubMed  Google Scholar 

  28. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101(7):452–74.

    PubMed  Google Scholar 

  29. van Akkooi AC, Voit CA, Verhoef C, Eggermont AM. New developments in sentinel node staging in melanoma: controversies and alternatives. Curr Opin Oncol. 2010;22(3):169–77.

    PubMed  Google Scholar 

  30. Guggenheim MM, Hug U, Jung FJ, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg. 2008;247(4): 687–93.

    PubMed  Google Scholar 

  31. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10(6): 676–80.

    PubMed  Google Scholar 

  32. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26(26):4296–303.

    PubMed  Google Scholar 

  33. Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15(4):1202–10.

    PubMed  Google Scholar 

  34. Scolyer RA, Li LX, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol. 2004;122(4):532–9.

    PubMed  Google Scholar 

  35. van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248(6):949–55.

    PubMed  Google Scholar 

  36. van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Nieweg OE. Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann Surg. 2009;250(2):301–4.

    PubMed  Google Scholar 

  37. van der Ploeg AP, van Akkooi AC, Schmitz PI, Koljenovic S, Verhoef C, Eggermont AM. EORTC melanoma group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur J Cancer. 2010;46(13): 2414–21.

    PubMed  Google Scholar 

  38. Murali R, Hughes MT, Fitzgerald P, Thompson JF, Scolyer RA. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly Clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg. 2009;249(4):641–7.

    PubMed  Google Scholar 

  39. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991;338(8777): 1227–9.

    PubMed  CAS  Google Scholar 

  40. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280(16):1410–5.

    PubMed  CAS  Google Scholar 

  41. Wang X, Heller R, VanVoorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994;220(6):768–74.

    PubMed  CAS  Google Scholar 

  42. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol. 1999;17(10):3238–44.

    PubMed  CAS  Google Scholar 

  43. Li W, Stall A, Shivers SC, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg. 2000;231(6):795–803.

    PubMed  CAS  Google Scholar 

  44. Ribuffo D, Gradilone A, Vonella M, et al. Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol. 2003;10(4):396–402.

    PubMed  Google Scholar 

  45. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction–staged sentinel lymph nodes from melanoma patients. J Clin Oncol. 2004;22(19):3989–96.

    PubMed  Google Scholar 

  46. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol. 2006;24(18): 2849–57.

    PubMed  CAS  Google Scholar 

  47. Mocellin S, Hoon DS, Pilati P, Rossi CR, Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol. 2007; 25(12):1588–95.

    PubMed  Google Scholar 

  48. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group. Wellington, 2008.

    Google Scholar 

  49. Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (<or  =  1 mm). Cancer. 2009;115(4): 869–79.

    PubMed  Google Scholar 

  50. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage Ib and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464–71.

    PubMed  Google Scholar 

  51. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3): 247–58.

    PubMed  Google Scholar 

  52. Mocellin S, Ambrosi A, Montesco MC, et al. Support vector machine learning model for the prediction of sentinel node status in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(8):1113–22.

    PubMed  Google Scholar 

  53. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100–8.

    PubMed  Google Scholar 

  54. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25(7):869–75.

    PubMed  Google Scholar 

  55. Kunte C, Geimer T, Baumert J, et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res. 2010;20(4):330–7.

    PubMed  Google Scholar 

  56. Faries MB, Wanek LA, Elashoff D, Wright BE, Morton DL. Predictors of occult nodal metastasis in patients with thin melanoma. Arch Surg. 2010;145(2):137–42.

    PubMed  Google Scholar 

  57. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.

    PubMed  Google Scholar 

  58. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21(19):3573–9.

    PubMed  CAS  Google Scholar 

  59. Grimm EA, Hoon DSB, McDivitt Duncan L. Biomarkers for melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S, Atkins MB, Thompson JF, editors. Cutaneous melanoma. St. Louis: Quality Medical Publishing; 2009. p. 883–95.

    Google Scholar 

  60. Mihic-Probst D, Mnich CD, Oberholzer PA, et al. P16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2006;118(9):2262–8.

    PubMed  CAS  Google Scholar 

  61. Rangel J, Nosrati M, Torabian S, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112(1):144–50.

    PubMed  Google Scholar 

  62. Simonetti O, Goteri G, Lucarini G, et al. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer. 2006;42(8):1181–7.

    PubMed  CAS  Google Scholar 

  63. Kaariainen E, Nummela P, Soikkeli J, et al. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol. 2006;210(2):181–91.

    PubMed  CAS  Google Scholar 

  64. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg. 2008;61(3):265–71.

    PubMed  CAS  Google Scholar 

  65. Rangel J, Torabian S, Shaikh L, et al. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol. 2006;24(28):4565–9.

    PubMed  CAS  Google Scholar 

  66. Weinlich G, Zelger B. Metallothionein overexpression, a highly significant prognostic factor in thin melanoma. Histopathology. 2007;51(2):280–3.

    PubMed  CAS  Google Scholar 

  67. Weinlich G, Topar G, Eisendle K, Fritsch PO, Zelger B. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol. 2007;21(5):669–77.

    PubMed  CAS  Google Scholar 

  68. Boone B, Haspeslagh M, Brochez L. Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF-beta resistance, in primary cutaneous melanoma. J Dermatol Sci. 2009;53(1):26–33.

    PubMed  CAS  Google Scholar 

  69. Rangel J, Nosrati M, Leong SP, et al. Novel role for RGS1 in melanoma progression. Am J Surg Pathol. 2008;32(8):1207–12.

    PubMed  Google Scholar 

  70. Liu B, Ma J, Wang X, et al. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma. Anat Rec (Hoboken). 2008;291(10):1227–35.

    CAS  Google Scholar 

  71. Massi D, Puig S, Franchi A, et al. Tumor lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol. 2006;59(2):166–73.

    PubMed  CAS  Google Scholar 

  72. Sahni D, Robson A, Orchard G, Szydlo R, Evans AV, Russell-Jones R. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status. J Clin Pathol. 2005;58(7):715–21.

    PubMed  CAS  Google Scholar 

  73. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166(3): 913–21.

    PubMed  CAS  Google Scholar 

  74. Schietroma C, Cianfarani F, Lacal PM, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer. 2003;98(4):789–97.

    PubMed  CAS  Google Scholar 

  75. Wobser M, Siedel C, Schrama D, Brocker EB, Becker JC, Vetter-Kauczok CS. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Arch Dermatol Res. 2006;297(8):352–7.

    PubMed  CAS  Google Scholar 

  76. Xu X, Gimotty PA, Guerry D, et al. Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol. 2008;39(6):901–9.

    PubMed  CAS  Google Scholar 

  77. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.

    PubMed  CAS  Google Scholar 

  78. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–5.

    PubMed  CAS  Google Scholar 

  79. Giorgadze TA, Zhang PJ, Pasha T, et al. Lymphatic vessel density is significantly increased in melanoma. J Cutan Pathol. 2004;31(10):672–7.

    PubMed  CAS  Google Scholar 

  80. Mehnert JM, McCarthy MM, Jilaveanu L, et al. Quantitative expression of VEGF, VEGFR-1, VEGFR-2, and VEGFR-3 in melanoma tissue microarrays. Hum Pathol. 2010;41(3):375–84.

    PubMed  CAS  Google Scholar 

  81. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res. 2003;9(1):250–6.

    PubMed  CAS  Google Scholar 

  82. Brychtova S, Bezdekova M, Brychta T, Tichy M. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma. 2008;55(4):273–9.

    PubMed  CAS  Google Scholar 

  83. Niakosari F, Kahn HJ, McCready D, et al. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma. Arch Dermatol. 2008;144(4):462–7.

    PubMed  Google Scholar 

  84. Boone B, Blokx W, De Bacquer D, Lambert J, Ruiter D, Brochez L. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch. 2008;453(3):257–65.

    PubMed  CAS  Google Scholar 

  85. Depasquale I, Thompson WD. Prognosis in human melanoma: Par-1 expression is superior to other coagulation components and VEGF. Histopathology. 2008;52(4):500–9.

    PubMed  CAS  Google Scholar 

  86. Chua R, Setzer S, Govindarajan B, Sexton D, Cohen C, Arbiser JL. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol. 2009;60(5): 758–66.

    PubMed  Google Scholar 

  87. Emmett MS, Symonds KE, Rigby H, et al. Prediction of melanoma metastasis by the Shields index based on lymphatic vessel density. BMC Cancer. 2010; 10(1):208.

    PubMed  Google Scholar 

  88. Cook MG, Green MA, Anderson B, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol. 2003;200(3):314–9.

    PubMed  Google Scholar 

  89. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol. 2008;25(2):100–11.

    PubMed  Google Scholar 

  90. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumors. Pathology. 2004;36(5):478–84.

    PubMed  Google Scholar 

  91. Roberts AA, Cochran AJ. Pathologic analysis of sentinel lymph nodes in melanoma patients: current and future trends. J Surg Oncol. 2004;85(3):152–61.

    PubMed  Google Scholar 

  92. Ranieri JM, Wagner JD, Azuaje R, et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol. 2002;9(10):975–81.

    PubMed  Google Scholar 

  93. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol. 2003;10(5): 575–81.

    PubMed  Google Scholar 

  94. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22(18):3677–84.

    PubMed  Google Scholar 

  95. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201(1):37–47.

    PubMed  Google Scholar 

  96. Pearlman NW, McCarter MD, Frank M, et al. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006;192(6):878–81.

    PubMed  Google Scholar 

  97. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006;17(10):1578–85.

    PubMed  Google Scholar 

  98. Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol. 2007;14(2): 906–12.

    PubMed  Google Scholar 

  99. Debarbieux S, Duru G, Dalle S, Beatrix O, Balme B, Thomas L. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol. 2007;157(1):58–67.

    PubMed  CAS  Google Scholar 

  100. Scheri RP, Essner R, Turner RR, Ye X, Morton DL. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol. 2007;14(10):2861–6.

    PubMed  Google Scholar 

  101. Roka F, Mastan P, Binder M, et al. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol. 2008;34(1):82–8.

    PubMed  CAS  Google Scholar 

  102. Satzger I, Volker B, Al Ghazal M, Meier A, Kapp A, Gutzmer R. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology. 2007;50(6):764–72.

    PubMed  CAS  Google Scholar 

  103. Guggenheim M, Dummer R, Jung FJ, et al. The influence of sentinel lymph node tumor burden on additional lymph node involvement and disease-free survival in cutaneous melanoma–a retrospective analysis of 392 cases. Br J Cancer. 2008;98(12): 1922–8.

    PubMed  CAS  Google Scholar 

  104. Glumac N, Hocevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. J Surg Oncol. 2008;98(1):46–8.

    PubMed  Google Scholar 

  105. Starz H, Siedlecki K, Balda BR. Sentinel lymphadenectomy and S-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol. 2004;11(3 Suppl):162S–8.

    PubMed  Google Scholar 

  106. Fink AM, Weihsengruber F, Spangl B, et al. S-classification of sentinel lymph node biopsy predicts the results of complete regional lymph node dissection. Melanoma Res. 2005;15(4):267–71.

    PubMed  Google Scholar 

  107. Satzger I, Volker B, Meier A, Kapp A, Gutzmer R. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol. 2008;15(6):1723–32.

    PubMed  Google Scholar 

  108. van der Ploeg IM, Kroon BB, Antonini N, Valdes Olmos RA, Nieweg OE. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? Ann Surg. 2009; 249(6):1003–7.

    PubMed  Google Scholar 

  109. Dewar DJ, Newell B, Green MA, Topping AP, Powell BW, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22(16):3345–9.

    PubMed  CAS  Google Scholar 

  110. Frankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol. 2008;15(9):2403–11.

    PubMed  Google Scholar 

  111. Cochran AJ, Wen DR, Huang RR, Wang HJ, Elashoff R, Morton DL. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17(7):747–55.

    PubMed  Google Scholar 

  112. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol. 2005;12(6):440–8.

    PubMed  Google Scholar 

  113. Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 2003;10(1):27–31.

    PubMed  Google Scholar 

  114. Starz H, Balda BR, Kramer KU, Buchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91(11):2110–21.

    PubMed  CAS  Google Scholar 

  115. Spillane AJ, Winstanley J, Thompson JF. Lymph node ratio in melanoma: a marker of variation in surgical quality? Cancer. 2009;115(11):2384–7.

    PubMed  Google Scholar 

  116. Wiener M, Acland KM, Shaw HM, et al. Sentinel node positive melanoma patients: prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model. Ann Surg Oncol. 2010;17(8):1995–2005.

    PubMed  Google Scholar 

  117. Murali R, Cochran AJ, Cook MG, et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer. 2009;115(21):5026–37.

    PubMed  Google Scholar 

  118. Di Tommaso L, Arizzi C, Rahal D, et al. Anatomic location of breast cancer micrometastasis in sentinel lymph node predicts axillary status. Ann Surg. 2006;243(5):706–7. author reply 706–707.

    PubMed  Google Scholar 

  119. Franco R, Cantile M, Scala S, et al. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biol Ther. 2010;9(6):423–9.

    PubMed  CAS  Google Scholar 

  120. Scolyer RA, Mihm MC, Cochran AJ, Busam KJ, McCarthy MM. Pathology of melanoma. In: Balch CM, Hounghton AB, Sober A, Soong S, Atkins MB, Thompson JF, editors. Cutaneous melanoma. St. Louis: Quality Medical Publishing; 2009. p. 205–48.

    Google Scholar 

  121. Goydos JS, Ravikumar TS, Germino FJ, Yudd A, Bancila E. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg. 1998;187(2):182–8. discussion 188–190.

    PubMed  CAS  Google Scholar 

  122. Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol. 1999;23(7):822–8.

    PubMed  CAS  Google Scholar 

  123. Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol. 2000;114(4):637–42.

    PubMed  CAS  Google Scholar 

  124. Palmieri G, Ascierto PA, Cossu A, et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol. 2001;19(5):1437–43.

    PubMed  CAS  Google Scholar 

  125. Boi S, Cristofolini P, Togni R, et al. Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk. Melanoma Res. 2002;12(2):147–53.

    PubMed  CAS  Google Scholar 

  126. Goydos JS. Prevention and early diagnosis of cutaneous melanoma. N J Med. 2000;97(5):37–40.

    PubMed  CAS  Google Scholar 

  127. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol. 2003;21(19):3566–72.

    PubMed  Google Scholar 

  128. Rimoldi D, Lemoine R, Kurt AM, et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res. 2003;13(5):511–20.

    PubMed  CAS  Google Scholar 

  129. Starz H, Haas CJ, Schulz GM, Balda BR. Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes. Mod Pathol. 2003;16(9):920–9.

    PubMed  Google Scholar 

  130. Blaheta HJ, Roeger S, Sotlar K, et al. Additional reverse transcription-polymerase chain reaction of peripheral slices is not superior to analysis of the central slice in sentinel lymph nodes from melanoma patients. Br J Dermatol. 2004;150(3):477–83.

    PubMed  CAS  Google Scholar 

  131. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22(13):2671–80.

    PubMed  CAS  Google Scholar 

  132. Ulrich J, Bonnekoh B, Bockelmann R, et al. Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer. 2004;40(18):2812–9.

    PubMed  CAS  Google Scholar 

  133. Abrahamsen HN, Sorensen BS, Nexo E, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA. Clin Cancer Res. 2005;11(4): 1425–33.

    PubMed  CAS  Google Scholar 

  134. Giese T, Engstner M, Mansmann U, Hartschuh W, Arden B. Quantification of melanoma micrometastases in sentinel lymph nodes using real-time RT-PCR. J Invest Dermatol. 2005;124(3):633–7.

    PubMed  CAS  Google Scholar 

  135. Romanini A, Manca G, Pellegrino D, et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol. 2005;16(11):1832–40.

    PubMed  CAS  Google Scholar 

  136. Mangas C, Hilari JM, Paradelo C, et al. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol. 2006;13(7):910–8.

    PubMed  Google Scholar 

  137. Denninghoff VC, Falco J, Kahn AG, Trouchot V, Curutchet HP, Elsner B. Sentinel node in melanoma patients: triple negativity with routine techniques and PCR as positive prognostic factor for survival. Mod Pathol. 2008;21(4):438–44.

    PubMed  CAS  Google Scholar 

  138. Riber-Hansen R, Abrahamsen HN, Sorensen BS, Hamilton-Dutoit SJ, Steiniche T. Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease-free survival. APMIS. 2008;116(3):199–205.

    PubMed  Google Scholar 

  139. Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol. 2008;159(3): 597–605.

    PubMed  CAS  Google Scholar 

  140. Hilari JM, Mangas C, Xi L, et al. Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time RT-PCR. Ann Surg Oncol. 2009; 16(1):177–85.

    PubMed  Google Scholar 

  141. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006;12(15): 4605–13.

    PubMed  CAS  Google Scholar 

  142. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.

    PubMed  Google Scholar 

  143. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452–9.

    PubMed  Google Scholar 

  144. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.

    PubMed  CAS  Google Scholar 

  145. Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III ­melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372(9633): 117–26.

    PubMed  CAS  Google Scholar 

  146. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905–10.

    PubMed  CAS  Google Scholar 

  147. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998; 16(4):1425–9.

    PubMed  CAS  Google Scholar 

  148. McMasters KM, Ross MI, Reintgen DS, et al. Final results of the Sunbelt Melanoma Trial. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol. 2008;26(Suppl):9003.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy

    Sandro Pasquali M.D. & Simone Mocellin M.D., Ph.D.

  2. Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Augustinus P. T. van der Ploeg M.Sc.

Authors
  1. Sandro Pasquali M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Augustinus P. T. van der Ploeg M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simone Mocellin M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Mocellin M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Health Center, Department of Dermatology, University of Connecticut, Farmington, 06030, Connecticut, USA

    Michael J. Murphy

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pasquali, S., van der Ploeg, A.P.T., Mocellin, S. (2012). Molecular Markers of Lymph Node Disease in Melanoma. In: Murphy, M. (eds) Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Current Clinical Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-433-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-433-3_16

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-432-6

  • Online ISBN: 978-1-60761-433-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation